Therefore, the possibility must be considered that CD28 abs lead to a worse response to IFN treatment by hampering IFN signalling, although in our study occurrence of CD28 abs did not correlate with response to IFN therapy in melanoma or hepatitis patients. The gene discussed is CD28; the disease is melanoma.